← Leaderboards
Henry S Sacks
Mount Sinai School Of Medicine Of Cuny
$12,251,247
Attributed
$12,251,247
Total exposure
34
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2005–14$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$12,251,247 · 34
By mechanism
M01$4,564,668 · 19
U01$3,549,528 · 9
R01$2,581,845 · 2
K07$857,786 · 1
R21$697,420 · 2
N01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Mount Sinai School Of Medicine Of Cuny
Same institution · by research overlap
- Xiu-Min Li$10,488,090
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHiv InfectionsHuman Therapy EvaluationAids TherapyAntiaids AgentDrug Screening /EvaluationAidsMicroorganism Disease ChemotherapyCombination ChemotherapyCooperative StudyPharmacokineticsAntiviral AgentsProtease InhibitorComorbidityOpportunistic InfectionsHuman Immunodeficiency Virus 1Clinical Trial Phase IImmunotherapyVirus LoadBlood ChemistryHelper T LymphocyteBiomarkerAlternative Medicine
Grant awards (81)
Meta-analysis of CAM therapies for HIV$406,927
R01 · FY2014 · AT · contact PI
Meta-analysis of CAM therapies for HIV$366,234
R01 · FY2013 · AT · contact PI
Meta-analysis of CAM therapies for HIV$377,561
R01 · FY2012 · AT · contact PI
Meta-analysis of CAM therapies for HIV$377,561
R01 · FY2011 · AT · contact PI
Meta-analysis of CAM therapies for HIV$380,541
R01 · FY2010 · AT · contact PI
EFFECTS OF A DIETARY SUPPLEMENT ON NON-SMALL CELL LUNG CANCER PATIENTS$1,224
M01 · FY2009 · RR · contact PI
WOMEN'S INTERAGENCY HIV STUDY(WIHS)$73,827
M01 · FY2007 · RR · contact PI
A PILOT STUDY OF SILYMARIN IN PATIENTS WITH HIV AND HCV$55,371
M01 · FY2007 · RR · contact PI
WOMEN'S INTERAGENCY HIV STUDY(WIHS) ($472,959
M01 · FY2006 · RR · contact PI
Prolong the Survival of NSCL Patients by a Phytomix$206,896
R01 · FY2006 · AT · contact PI
A PILOT STUDY OF SILYMARIN IN PATIENTS WITH HIV AND HCV$150,272
M01 · FY2006 · RR · contact PI
WIHS CARDIOVASCULAR COMPONENT$6,326
M01 · FY2006 · RR · contact PI
WOMEN'S INTERAGENCY HIV STUDY (WIHS)$660,980
M01 · FY2005 · RR
Prolong the Survival of NSCL Patients by a Phytomix$254,250
R01 · FY2005 · AT
Pilot Trial of Silymarin in Patients with HCV and HIV$211,875
R21 · FY2005 · NR
Leadership Award in Complementary and Alternative Medic$172,827
K07 · FY2005 · AT
A PILOT STUDY OF SILYMARIN IN PATIENTS WITH HIV AND HCV$102,605
M01 · FY2005 · RR
Prolong the Survival of NSCL Patients by a Phytomix$211,875
R01 · FY2004 · AT
Pilot Trial of Silymarin in Patients with HCV and HIV$211,875
R21 · FY2004 · NR
Leadership Award in Complementary and Alternative Medic$171,872
K07 · FY2004 · AT
Collaborative HIV/AIDS Development Project India$114,595
R21 · FY2004 · AT
Leadership Award in Complementary and Alternative Medic$170,939
K07 · FY2003 · AT
Collaborative HIV/AIDS Development Project India$159,075
R21 · FY2003 · AT
ACTG 301 TRIAL OF MEMANTINE FOR AIDS DEMENTIA COMPLEX (ADC)$206,718
M01 · FY2002 · RR
ACTG 398 PHASE II TRIAL OF AMPRENAVIR ABACAVIR, EFAVIRENZ &ADEFOVIR$206,718
M01 · FY2002 · RR
PHASE III TRIAL OF EFAVIRENZ OR NELFINAVIR LAMIVUDINE &ZIDOVUDINE$206,718
M01 · FY2002 · RR
ACTG 362 TRIAL TO DETERMINE EFFICACY OF AZITHROMYCIN PROPHYLAXIS$206,718
M01 · FY2002 · RR
ACTG 372 PHASE II STUDY OF PROLONGATION OF VIROLOGIC ROLLOVER FOR ACT$206,718
M01 · FY2002 · RR
ACTG 309 PHARMACOKINETICS OF ANTITUBERCULOSIS AGENTS IN HIV INFECTED$206,718
M01 · FY2002 · RR
Leadership Award in Complementary and Alternative Medic$170,022
K07 · FY2002 · AT
ACTG 364--COMPARISON OF THE VIROLOGIC EFFICACY OF NELFINAVIR AND/OR DMP 266$0
M01 · FY2002 · RR
PI &NNRTI IN HIV INFECTION$0
M01 · FY2002 · RR
ACTG 328--STUDY OF INTERMT. rhIL-2 COMPARED TO HAART$0
M01 · FY2002 · RR
ACTG 323--FLUCONAZOLE AS CHRONIC SUPP. THERAPY VS. EPISODIC THERAPY IN HIV+ PTS$0
M01 · FY2002 · RR
ACTG 291--TRIAL OF ru HUMAN NERVE GF IN HIV ASSOC. PERPH. NEUROPATHY$0
M01 · FY2002 · RR
PROTEASE INHIBITOR/METHADONE METABOLISM IN HIV INFECTION$0
M01 · FY2002 · RR
ACTG 362 TRIAL TO DETERMINE EFFICACY OF AZITHROMYCIN PROPHYLAXIS$206,718
M01 · FY2001 · RR
ACTG 309 PHARMACOKINETICS OF ANTITUBERCULOSIS AGENTS IN HIV INFECTED$206,718
M01 · FY2001 · RR
ACTG 301 TRIAL OF MEMANTINE FOR AIDS DEMENTIA COMPLEX (ADC)$206,718
M01 · FY2001 · RR
ACTG 372 PHASE II STUDY OF PROLONGATION OF VIROLOGIC ROLLOVER FOR ACT$206,718
M01 · FY2001 · RR
PHASE III TRIAL OF EFAVIRENZ OR NELFINAVIR LAMIVUDINE &ZIDOVUDINE$206,718
M01 · FY2001 · RR
ACTG 398 PHASE II TRIAL OF AMPRENAVIR ABACAVIR, EFAVIRENZ &ADEFOVIR$206,718
M01 · FY2001 · RR
OUTCOMES COMMITTEE AGENDA$197,196
U01 · FY2001 · AI
OUTREACH AGENDA$197,196
U01 · FY2001 · AI
CORE--ADVANCED TECHNOLOGY LABORATORIES$197,196
U01 · FY2001 · AI
WOMEN'S HEALTH AGENDA$197,196
U01 · FY2001 · AI
PHARMACOLOGY AGENDA$197,196
U01 · FY2001 · AI
IMMUNOLOGY AND IMMUNE BASED THERAPY AGENDA$197,196
U01 · FY2001 · AI
NEUROLOGY AGENDA$197,196
U01 · FY2001 · AI
COMPLICATIONS OF HIV DISEASE AGENDA$197,196
U01 · FY2001 · AI
HIV DISEASE RESEARCH AGENDA$197,196
U01 · FY2001 · AI
Leadership Award in Complementary and Alternative Medic$172,126
K07 · FY2001 · AT
PI &NNRTI IN HIV INFECTION$0
M01 · FY2001 · RR
PROTEASE INHIBITOR/METHADONE METABOLISM IN HIV INFECTION$0
M01 · FY2001 · RR
VIRAL ACTIVATION TRANSFUSION STUDY$0
N01 · FY2001 · HB
ACTG 364--COMPARISON OF THE VIROLOGIC EFFICACY OF NELFINAVIR AND/OR DMP 266$0
M01 · FY2001 · RR
ACTG 323--FLUCONAZOLE AS CHRONIC SUPP. THERAPY VS. EPISODIC THERAPY IN HIV+ PTS$0
M01 · FY2001 · RR
ACTG 328--STUDY OF INTERMT. rhIL-2 COMPARED TO HAART$0
M01 · FY2001 · RR
ACTG 291--TRIAL OF ru HUMAN NERVE GF IN HIV ASSOC. PERPH. NEUROPATHY$0
M01 · FY2001 · RR
OUTREACH AGENDA$197,196
U01 · FY2000 · AI
CORE--ADVANCED TECHNOLOGY LABORATORIES$197,196
U01 · FY2000 · AI
OUTCOMES COMMITTEE AGENDA$197,196
U01 · FY2000 · AI
WOMEN'S HEALTH AGENDA$197,196
U01 · FY2000 · AI
PHARMACOLOGY AGENDA$197,196
U01 · FY2000 · AI
IMMUNOLOGY AND IMMUNE BASED THERAPY AGENDA$197,196
U01 · FY2000 · AI
NEUROLOGY AGENDA$197,196
U01 · FY2000 · AI
COMPLICATIONS OF HIV DISEASE AGENDA$197,196
U01 · FY2000 · AI
HIV DISEASE RESEARCH AGENDA$197,196
U01 · FY2000 · AI
ACTG 323--FLUCONAZOLE AS CHRONIC SUPP. THERAPY VS. EPISODIC THERAPY IN HIV+ PTS$68,788
M01 · FY2000 · RR
ACTG 291--TRIAL OF ru HUMAN NERVE GF IN HIV ASSOC. PERPH. NEUROPATHY$68,788
M01 · FY2000 · RR
ACTG 364--COMPARISON OF THE VIROLOGIC EFFICACY OF NELFINAVIR AND/OR DMP 266$68,788
M01 · FY2000 · RR
ACTG 328--STUDY OF INTERMT. rhIL-2 COMPARED TO HAART$68,788
M01 · FY2000 · RR
ACTG 398 PHASE II TRIAL OF AMPRENAVIR ABACAVIR, EFAVIRENZ &ADEFOVIR$47,556
M01 · FY2000 · RR
PHASE III TRIAL OF EFAVIRENZ OR NELFINAVIR LAMIVUDINE &ZIDOVUDINE$47,556
M01 · FY2000 · RR
ACTG 309 PHARMACOKINETICS OF ANTITUBERCULOSIS AGENTS IN HIV INFECTED$47,556
M01 · FY2000 · RR
ACTG 362 TRIAL TO DETERMINE EFFICACY OF AZITHROMYCIN PROPHYLAXIS$47,556
M01 · FY2000 · RR
ACTG 372 PHASE II STUDY OF PROLONGATION OF VIROLOGIC ROLLOVER FOR ACT$47,556
M01 · FY2000 · RR
ACTG 301 TRIAL OF MEMANTINE FOR AIDS DEMENTIA COMPLEX (ADC)$47,556
M01 · FY2000 · RR
VIRAL ACTIVATION TRANSFUSION STUDY$0
N01 · FY2000 · HB
PI &NNRTI IN HIV INFECTION$0
M01 · FY2000 · RR
PROTEASE INHIBITOR/METHADONE METABOLISM IN HIV INFECTION$0
M01 · FY2000 · RR